Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionDaniel K. Wells, Elham Sherafat, Marit M. van Buuren et al.|Cell|2020Cited by 534
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAdam J. Schoenfeld, Matthew D. Hellmann, Kathryn C. Arbour et al.|Annals of Oncology|2019Cited by 413
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Joseph M. Chan et al.|Clinical Cancer Research|2020Cited by 381